Maxim Group reissued their hold rating on shares of Can Fite Biopharma (NYSEAMERICAN:CANF) in a research report released on Friday. They currently have a $7.00 price objective on the biotechnology company’s stock.
“While we anticipated CanFite would need to raise capital we did not anticipate the added dilution announced in today’s raise and the potential impact of raising too little capital which sets up additional dilution.”,” Maxim Group’s analyst commented.
Separately, HC Wainwright restated a buy rating and issued a $6.00 price objective on shares of Can Fite Biopharma in a research note on Thursday, February 1st.
An institutional investor recently bought a new position in Can Fite Biopharma stock. Meitav Dash Investments Ltd. purchased a new stake in shares of Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned 0.93% of Can Fite Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 5.12% of the company’s stock.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.